Based on the data reported here, Ad-TK and Ad-Flt3L have now been chosen for further downstream process development, manufactured under good clinical manufacturing processes, and will be tested in early phase clinical trials for the treatment of resectable, recurrent glioma in the near future. This evidence concerns the gene FLT3LG and central nervous system cancer.